Sphenopalatine Ganglion Acupuncture for Allergic Rhinitis
Condition(s) studied
Investigational drug(s) / intervention(s)
Sphenopalatine Ganglion Acupuncture: Sphenopalatine ganglion acupuncture will be performed twice weekly for 4 consecutive weeks, for a total of 8 treatment sessions. Acupuncture will be performed alternately on the left and right sides without needle retention.
Mometasone furoate nasal spray: Mometasone furoate nasal spray will be administered as two sprays into each nostril once daily for 4 consecutive weeks.
Study summary
Allergic rhinitis can cause sneezing, a runny or blocked nose, and nasal itching, which may affect daily activities and quality of life. Nasal corticosteroid sprays are commonly used to control these symptoms, but some people may still have bothersome symptoms.
The purpose of this study is to find out whether adding sphenopalatine ganglion acupuncture to mometasone furoate nasal spray can improve allergic rhinitis symptoms more than using the nasal spray alone, and to evaluate the safety of this treatment.
Adults with moderate-to-severe perennial allergic rhinitis will be randomly assigned to one of two treatment groups. Both groups will use mometasone furoate nasal spray for 4 weeks. Participants in one group will also receive sphenopalatine ganglion acupuncture twice a week for 4 weeks. Researchers will compare changes in nasal symptoms, quality of life, use of rescue medication, clinical examination findings, and adverse events between the two groups. Participants will also be followed after treatment to assess whether the treatment effects are maintained.
Eligibility
Primary outcome measure(s)
- Change From Baseline in Total Nasal Symptom Score — Baseline, Week 2, Week 4, Week 8 and Month 6.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Zhongshan Torch Development Zone People's Hospital | Zhongshan | Guangdong |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07784491 on ClinicalTrials.gov ↗ ← All trials in China